Targeted therapies articles from across Nature Portfolio

African American patients were under-represented in the studies that led to the current patient classification system for acute myeloid leukemia (AML). A new in-depth analysis of the genetics of AML in African Americans suggests that this omission has implications for patient care.

The identification of treatments that selectively co-inhibit cancerous cell populations remains a challenge. Here, a machine learning approach, scTherapy, leverages single-cell transcriptomic profiles to prioritize multi-targeting treatment options for individual patients with hematological cancers or solid tumors.

African American patients were under-represented in the studies that led to the current patient classification system for acute myeloid leukemia (AML). A new in-depth analysis of the genetics of AML in African Americans suggests that this omission has implications for patient care.

Despite recent FDA approval, the clinical utility of vorasidenib in the treatment of IDH-mutant low-grade gliomas remains unclear. Herein, we critique the pivotal trial of vorasidenib, and highlight the questionable choice of control intervention and end points, ethical concerns, as well as the uncertain efficacy observed, and argue that the approval might be premature given the high cost of this drug and lack of clear benefit over standard treatments.

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.